{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:01:38Z","timestamp":1785168098280,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.autrev.2026.104100","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:29:03Z","timestamp":1779676143000},"page":"104100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Depression in mastocytosis: A neglected dimension of a clonal mast cell disease"],"prefix":"10.1016","volume":"25","author":[{"given":"Petr","family":"Heneberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2026.104100_bb0005","first-page":"159","article-title":"Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10654-024-01195-5","article-title":"Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study","volume":"40","author":"J\u00f8rgensen","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.autrev.2026.104100_bb0015","doi-asserted-by":"crossref","first-page":"31406","DOI":"10.2340\/1651-226X.2024.31406","article-title":"Epidemiology of mastocytosis: a population-based study (Sweden)","volume":"63","author":"Bergstr\u00f6m","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.autrev.2026.104100_bb0020","series-title":"Epidemiology of systemic mastocytosis (SM) and indolent systemic mastocytosis (ISM) in Germany. Poster presented at: ISPOR Europe 2023, 12\u201315 November 2023, Copenhagen, Denmark Poster EPH79","author":"Herold","year":"2023"},{"issue":"12","key":"10.1016\/j.autrev.2026.104100_bb0025","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.autrev.2026.104100_bb0030","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2026.104100_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2016.03.013","article-title":"Mastocytosis in adulthood and neuropsychiatric disorders","volume":"174","author":"Georgin-Lavialle","year":"2016","journal-title":"Transl Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-021-01747-y","article-title":"Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients","volume":"16","author":"Jendoubi","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.autrev.2026.104100_bb0045","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1016\/j.cell.2025.06.045","article-title":"A mast cell receptor mediates post-stroke brain inflammation via a dural-brain axis","volume":"188","author":"Kothari","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104100_bb0050","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1016\/j.cell.2025.06.046","article-title":"Mast cells regulate the brain-dura interface and cerebrospinal fluid dynamics","volume":"188","author":"Mamuladze","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0060","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2741\/2174","article-title":"Corticotropin-releasing hormone and the blood\u2013brain-barrier","volume":"12","author":"Theoharides","year":"2007","journal-title":"Front Biosci"},{"issue":"30","key":"10.1016\/j.autrev.2026.104100_bb0065","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1523\/JNEUROSCI.2618-20.2021","article-title":"Inflammation-induced histamine impairs the capacity of escitalopram to increase hippocampal extracellular serotonin","volume":"41","author":"Hersey","year":"2021","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104100_bb0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00213-013-3146-1","article-title":"Histamine H\u2081 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers","volume":"230","author":"Sato","year":"2013","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.autrev.2026.104100_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104100_bb0080","series-title":"Patient diagnostic journey of systemic mastocytosis in Europe: results from the PRISM survey. Poster presented at: European Hematology Association (EHA) Annual Congress, 13\u201316 June 2024a, Madrid, Spain. Poster P2292","author":"Radia","year":"2024"},{"key":"10.1016\/j.autrev.2026.104100_bb0085","series-title":"The burden of systemic mastocytosis in Europe: results from the PRISM patient survey. Poster presented at: European Hematology Association (EHA) Annual Congress, 13\u201316 June 2024b, Madrid, Spain. Poster P1676","author":"Radia","year":"2024"},{"key":"10.1016\/j.autrev.2026.104100_bb0090","series-title":"Oral presentation at: European Academy of allergy and clinical immunology (EAACI) annual meeting, 31 May\u20133 June 2024, Valencia, Spain","article-title":"The burden of indolent systemic mastocytosis in Europe: Results from the PRISM patient survey","author":"Triggiani","year":"2024"},{"key":"10.1016\/j.autrev.2026.104100_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13601-019-0278-3","article-title":"Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis","volume":"9","author":"Konstantinou","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.autrev.2026.104100_bb0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2018.08.063","article-title":"Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis","volume":"80","author":"Patel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2026.104100_bb0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2026.104100_bb0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpsychores.2016.06.001","article-title":"Depression and anxiety in patients with inflammatory bowel disease: a systematic review","volume":"87","author":"Neuendorf","year":"2016","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.autrev.2026.104100_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/7854_2016_7","article-title":"Depression in autoimmune diseases","volume":"31","author":"Pryce","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104100_bb0120","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas","year":"2008","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.smrv.2010.06.004","article-title":"Histamine in the regulation of wakefulness","volume":"15","author":"Thakkar","year":"2011","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.autrev.2026.104100_bb0130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.psyneuen.2018.11.007","article-title":"Chronic histamine 3 receptor antagonism alleviates depression-like conditions in mice via modulation of brain-derived neurotrophic factor and hypothalamus\u2013pituitary\u2013adrenal axis","volume":"101","author":"Kumar","year":"2019","journal-title":"Psychoneuroendocrinology"},{"issue":"7","key":"10.1016\/j.autrev.2026.104100_bb0135","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0701740","article-title":"Antidepressant-like effects of endogenous histamine and of two histamine H1 receptor agonists in the mouse forced swim test","volume":"123","author":"Lamberti","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.106.111039","article-title":"BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology","volume":"320","author":"Ligneau","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2026.104100_bb0145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1742-2094-10-142","article-title":"Neurovascular unit dysfunction with blood\u2013brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence","volume":"10","author":"Najjar","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000335178","article-title":"Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells","volume":"159","author":"Zhang","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0006-8993(00)03026-2","article-title":"Acute stress increases permeability of the blood\u2013brain-barrier through activation of brain mast cells","volume":"888","author":"Esposito","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.autrev.2026.104100_bb0160","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fnins.2017.00703","article-title":"Mast cell activation in brain injury, stress, and post-traumatic stress disorder and Alzheimer\u2019s disease pathogenesis","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front Neurosci"},{"issue":"9","key":"10.1016\/j.autrev.2026.104100_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tins.2008.06.006","article-title":"The HPA axis in major depression: classical theories and new developments","volume":"31","author":"Pariante","year":"2008","journal-title":"Trends Neurosci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104100_bb0170","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0301-0082(00)00039-3","article-title":"The physiology of brain histamine","volume":"63","author":"Brown","year":"2001","journal-title":"Prog Neurobiol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104100_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0166-4328(96)00059-9","article-title":"Long-term depletion of brain histamine induced by \u03b1-fluoromethylhistidine increases feeding-associated locomotor activity in mice with a modulation of brain amino acid levels","volume":"72","author":"Sakai","year":"1995","journal-title":"Behav Brain Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104100_bb0180","first-page":"355","article-title":"Inhibition of brain histamine synthesis increases food intake and attenuates vasopressin response to salt loading in rats","volume":"16","author":"Tuomisto","year":"1994","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1523\/JNEUROSCI.20-01-00401.2000","article-title":"Mast cells migrate from blood to brain","volume":"20","author":"Silverman","year":"2000","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104100_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033805","article-title":"Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans","volume":"7","author":"Weng","year":"2012","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.autrev.2026.104100_bb0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s002109900097","article-title":"Histaminergic neurons modulate acetylcholine release in the ventral striatum: role of H3 histamine receptors","volume":"360","author":"Prast","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104100_bb0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1517\/14728220903188438","article-title":"Histamine H3 and H4 receptors as novel drug targets","volume":"18","author":"Tiligada","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"46","key":"10.1016\/j.autrev.2026.104100_bb0205","doi-asserted-by":"crossref","first-page":"18053","DOI":"10.1073\/pnas.0809479105","article-title":"Brain mast cells link the immune system to anxiety-like behavior","volume":"105","author":"Nautiyal","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.autrev.2026.104100_bb0210","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41598-025-86959-z","article-title":"Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system","volume":"15","author":"Mao","year":"2025","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.autrev.2026.104100_bb0215","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.autrev.2026.104100_bb0220","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104100_bb0225","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104100_bb0230","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.4049\/jimmunol.176.11.7062","article-title":"The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells","volume":"176","author":"Dunford","year":"2007","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104100_bb0235","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"2 Suppl","key":"10.1016\/j.autrev.2026.104100_bb0240","first-page":"AB171","article-title":"Avapritinib continues to demonstrate durable symptom control with a well-tolerated safety profile: long-term outcomes from PIONEER","volume":"157","author":"Akin","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2026.104100_bb0245","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104100_bb0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood-2025-80","article-title":"Efficacy and safety results from the primary analysis of the pivotal SUMMIT trial: bezuclastinib in adults with non-advanced systemic mastocytosis","volume":"146","author":"Rein","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104100_bb0255","author":"Blueprint Medicines Corporation"},{"issue":"26","key":"10.1016\/j.autrev.2026.104100_bb0260","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104100_bb0265","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104100_bb0270","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.autrev.2026.104100_bb0275","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/jpm13111562","article-title":"Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series","volume":"13","author":"Weinstock","year":"2023","journal-title":"J Pers Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104100_bb0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11882-024-01127-z","article-title":"Cognitive impairment and depression in mastocytosis: a synthesis of the literature","volume":"24","author":"Nicoloro-SantaBarbara","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.autrev.2026.104100_bb0285","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fncel.2019.00345","article-title":"Mast cells in gut and brain and their potential role as an emerging therapeutic target for neural diseases","volume":"13","author":"Traina","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"10069","key":"10.1016\/j.autrev.2026.104100_bb0290","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722600114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:42:24Z","timestamp":1785166944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722600114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S156899722600114X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104100","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depression in mastocytosis: A neglected dimension of a clonal mast cell disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104100"}}